Eugia US
Eugia US LLC is a specialty pharmaceutical subsidiary of Aurobindo Pharma that develops, manufactures, and distributes FDA-approved generic injectable pharmaceuticals to US hospitals, health systems, GPOs, and wholesalers, with 184 ANDA approvals and an oncology-expanding product pipeline.
- Company typePrivate
- Founded2022
- HeadquartersWindsor, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Eugia US does
Eugia US LLC is a specialty pharmaceutical company headquartered in East Windsor, New Jersey, and a wholly-owned subsidiary of Aurobindo Pharma Ltd. (BSE/NSE: AUROBINDO), one of India's largest generic manufacturers. Operating under the Eugia Pharma Specialities Limited umbrella following an August 2022 rebranding from AuroMedics Pharma LLC, Eugia US develops, manufactures, and distributes FDA-approved generic injectable pharmaceuticals to US healthcare institutions, including acute care hospitals, health systems, GPOs, independent hospitals, long-term care facilities, surgery and rehabilitation centers, and outpatient clinics. Its therapeutic portfolio spans antibiotics, antivirals, respiratory agents, hematology, cardiovascular, central nervous system, and oncology treatments, with an explicit product strategy aimed at in-demand and short-supply categories. The group has accumulated 184 ANDA approvals across its manufacturing facilities, with its portfolio extending into ready-to-use formulations such as Cyclophosphamide and higher-value oncology adjacencies including Pomalidomide Capsules (US market estimated at $3.3 billion) and Everolimus Tablets (184th ANDA, $78 million market, Q1 FY27 launch).
Distribution is hybrid: direct ordering via phone, fax, and email — with same-day shipping for orders placed before 12:00 PM EST — plus wholesale routing through AmerisourceBergen, Cardinal, McKesson, and M&D. Products are invoiced at published Wholesale Acquisition Cost with a $500 minimum order, and the commercial organization layers Territory Business Managers across defined US geographies (Ohio Valley, Florida, Texas/Oklahoma, Mid-Atlantic) with Strategic Account Managers handling national IDNs and GPO relationships. The company maintains a 59-acre, fully automated distribution center in East Windsor, NJ.
The business model is a one-time unit-pricing sale of generic injectable SKUs into institutional channels, with economics tied to volume share within hospital formularies and GPO contracts. In May 2024 Eugia US divested a manufacturing facility to Empower Pharma for $52 million as part of an asset-restructuring move, while continuing to grow its commercial product portfolio. Recent product launches (Pomalidomide, Everolimus, Bendamustine, Cyclophosphamide, Plerixafor) and ongoing TBM and sales-leadership hiring point to a deliberate mix shift toward higher-value specialty and oncology generics. There is no disclosed use of artificial intelligence or machine learning in the company's operations, R&D, or commercial functions.
Eugia US firmographics
Firmographics- Name
- Eugia US
- Legal name
- Eugia US LLC
- Website
- https://eugiaus.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Eugia US LLC is a specialty pharmaceutical subsidiary of Aurobindo Pharma that develops, manufactures, and distributes FDA-approved generic injectable pharmaceuticals to US hospitals, health systems, GPOs, and wholesalers, with 184 ANDA approvals and an oncology-expanding product pipeline.
- Ownership category
- akta.pro rank
Eugia US industry classification
Industry- Product category
- Generic Injectable Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (42345)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Generic Hospital & Institutional Products (HLAIABAL)
- akta.pro secondary industry
- Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)
Keywords
Where Eugia US is headquartered
LocationHeadquarters
- HQ city
- Windsor
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Eugia US business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure
Revenue model
- Generic Injectable Pharmaceutical Sales: Eugia US generates revenue through the manufacture and sale of FDA-approved generic injectable pharmaceuticals. Products are sold to healthcare institutions including hospitals, long-term care facilities, surgery and rehabilitation centers, and outpatient clinics through direct sales and wholesale distribution.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Wholesale Acquisition Cost pricing |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
Eugia US product offering
Product offeringCore offering
Eugia US develops, manufactures, markets, and distributes FDA-approved generic injectable pharmaceuticals across therapeutic classes including antibiotics, antivirals, respiratory, hematology, cardiovascular, central nervous system, and oncology treatments. Products are sold to acute care hospitals, long-term care facilities, surgery and rehabilitation centers, and outpatient clinics through direct sales and wholesale distribution channels.
Product overview
Eugia US (a subsidiary of Aurobindo Pharma, formerly AuroMedics Pharma LLC) is a specialty pharmaceutical company focused on manufacturing and marketing generic injectable medications. The company offers an extensive portfolio targeting in-demand, short-supply products across therapeutic categories including antibiotics, antivirals, respiratory agents, hematology, cardiovascular drugs, central nervous system medications, and oncology treatments. Products serve institutional settings including acute care hospitals, long-term care facilities, surgery and rehabilitation centers, and outpatient clinics. The portfolio includes injectables like Icatibant Injection, Carboprost Tromethamine, Vancomycin, Amphotericin B Liposome, Cyclophosphamide, and numerous other generic sterile injectables. Eugia operates with a focus on high-quality products, competitive pricing, and consistent supply.
Differentiator
Problem solved
Functional benefit
Products and services
- Generic Injectables Portfolio
Companies that use Eugia US
Customer profileSegments4 records
Ideal customer profiles4 records
Eugia US technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Eugia US partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Empower PharmaminorIn May 2024, US-based Empower Pharma acquired manufacturing assets from Eugia US LLC, a subsidiary of Aurobindo Pharma Ltd., for $52 million. The acquisition was intended to strengthen Empower's capacity in sterile medication production for maternal health therapeutics. The deal involved Eugia's manufacturing facility in New Jersey.
Scale indicators2 records
Recent moves8 records
Expansion highlights5 records
Eugia US competitors and assessment
Company assessmentBroad incumbents
- Viatris (formerly Mylan): Large diversified generic manufacturer with a sterile injectables franchise that overlaps Eugia US's portfolio; notably acquired and transferred products to Eugia historically, and competes for the same institutional customers.
- Baxter International: Major supplier of injectable and infusion pharmaceuticals to US hospitals, with overlapping presence in anesthesia, critical care, and oncology injectables served by Eugia US.
- Teva Pharmaceutical Industries: Global generic powerhouse with a broad sterile injectables portfolio in the US; competes with Eugia US across multiple therapeutic classes, particularly through GPO and hospital channels.
- Sandoz (Novartis): Global generic pharmaceuticals leader with a large sterile injectables business serving US hospitals; competes broadly with Eugia US across most therapeutic categories but at significantly greater scale and breadth.
- Pfizer (Hospira): Through the Hospira acquisition, Pfizer operates one of the largest US injectable pharmaceutical businesses, directly competing with Eugia US in oncology, anti-infectives, and other sterile injectable categories.
Direct peers
- Fresenius Kabi: One of the largest US suppliers of generic injectable pharmaceuticals, with a comparable sterile injectables portfolio across hospitals, GPOs and IDNs — directly competing with Eugia US across antibiotics, analgesics, and oncology injectables.
- Hikma Pharmaceuticals: Major US generic injectable manufacturer with overlapping hospital-channel focus and a comparable portfolio of sterile injectables, including short-supply and specialty products targeted at the same institutional customers as Eugia US.
- Apotex: Canadian-headquartered generic pharmaceutical company with a US injectables presence, overlapping portfolio of sterile injectables and competing for the same institutional and GPO contracts.
- Amphastar Pharmaceuticals: US-focused specialty injectable pharmaceutical company with a similar hospital-channel strategy and overlapping injectable portfolio, including products addressing shortage-prone therapeutic categories.
Emerging players
- Gland Pharma: India-based sterile injectables manufacturer with growing US presence (now part of Fosun), competing in similar injectable therapeutic categories and leveraging comparable cost advantages to Aurobindo/Eugia.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Eugia US social profiles
Digital presenceEugia US financial estimates
Financial estimateRevenue estimate
Valuation estimate
Eugia US leadership team
Management profileNumber of profiles
Profiles15 records
Eugia US funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Eugia US M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Eugia US
What does Eugia US do?
Eugia US develops, manufactures, markets, and distributes FDA-approved generic injectable pharmaceuticals across therapeutic classes including antibiotics, antivirals, respiratory, hematology, cardiovascular, central nervous system, and oncology treatments. Products are sold to acute care hospitals, long-term care facilities, surgery and rehabilitation centers, and outpatient clinics through direct sales and wholesale distribution channels.
Is Eugia US a public or private company?
Eugia US is a private company. It is classified as corporate owned and is currently operating.
When was Eugia US founded?
Eugia US was founded in 2022. It employs 101 to 250 people.
Where is Eugia US based?
Eugia US is headquartered in Windsor, United States, in the North America region.
How does Eugia US make money?
One revenue line is on record: generic Injectable Pharmaceutical Sales.
Who are Eugia US's main competitors?
Broad incumbents on record are Viatris (formerly Mylan), Baxter International, Teva Pharmaceutical Industries, Sandoz (Novartis) and Pfizer (Hospira). Direct peers are Fresenius Kabi, Hikma Pharmaceuticals, Apotex and Amphastar Pharmaceuticals. Gland Pharma is listed as an emerging player.
Does Eugia US have an API?
No public API is recorded for Eugia US.
What industry is Eugia US in?
Eugia US's product category is Generic Injectable Pharmaceuticals. Its primary akta.pro industry code is HLAIABAL, Generic Hospital & Institutional Products, with a secondary code of HLAIACAO, Specialty Injectable & Infusion Therapies (Cross-therapeutic). Its NAICS code is 325412 and its SIC code is 2834.